PharmAust Launches Interactive Investor Hub
Released
Released
Announcement PDF
PharmAust Launches Interactive Investor Hub
18 December 2023: PharmAust Limited (ASX: PAA), a clinical-stage biotechnology company, today
announced the launch of its new Investor Hub. The interactive platform will allow existing and
prospective shareholders to better engage with the company.
PharmAust’s Investor Hub will host the latest company announcements, presentations, news and
interviews. The interactive portal is also an opportunity for PharmAust’s investor community to pose
questions and comments directly to the company regarding news and updates on the portal.
PharmAust CEO, Dr Michael Thurn, said: “As PharmAust continues to see promising results in its
clinical trials we feel it is important to give our investor community an easy way to keep up to date with
company while maintaining an open channel of communication with the PharmAust team.”
Interested stakeholders are encouraged to sign
https://investorhub.pharmaust.com/auth/signup.
up
for
PharmAust’s
Investor
Hub at:
The Board authorises this announcement.
Enquiries:
Dr Michael Thurn
Chief Executive Officer
investorenquiries@pharmaust.com
P +61 (8) 9202 6814
F +61 (8) 9467 6111
www.pharmaust.com
About PharmAust Limited:
PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage
biotechnology company developing therapeutics for human and animal health applications. The company is
focused on repurposing monepantel (MPL) for human neurodegenerative diseases and treating cancer in dogs.
MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in cell growth and
proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning
process”, where toxic protein is broken down into macromolecules to be reused. This autophagic process is
disrupted in most neurodegenerative diseases, including motor neurone disease (MND/ALS).
PAA’s lead MPL program is for the treatment of MND/ALS, a rare, incurable disease. The company is currently
completing a Phase 1 study in patients with MND/ALS. Top-line results are expected to be announced in Q1
CY2024. PAA anticipates starting a Phase 2 study in H1 2024 that could lead to accelerated approval with the
US Food and Drug Administration in 2026. PAA is preparing to start a pivotal field trial in dogs with B-Cell
Lymphoma to enable product registration in the US in 2025. PAA has previously successfully completed a Phase
1 oncology clinical study of monepantel in humans and pilot studies in canine cancer.
PharmAust Limited ABN 35 094 006 023. Suite 116, 1 Kyle Way, Claremont, Western Australia
Tel: 08 9202 6814 Fax: 08 9467 6111
www.pharmaust.com
Share your feedback
Discover